Gallbladder cancer integrated bioinformatics analysis of protein profile data
Gastroenterology and Hepatology from Bed to Bench,
Vol. 12 No. Supplement 1 (2019),
7 December 2019
,
Page 66-73
https://doi.org/10.22037/ghfbb.v12i0.1811
Abstract
Aim: Identifying the critical genes that differentiate gall bladder cancer from a normal gall bladder and the related biological terms was the aim of this study.
Background: The molecular mechanism underlying gall bladder cancer (GBC) trigger and development still requires investigations. Potential therapeutic biomarkers can be identified through protein-protein interaction network prediction of proteome as a complementary study.
Methods: Here, a literature review of proteomics studies of gall bladder cancer from 2010 to 2019 was undertaken to screen differentially expressed proteins in this cancer. A network of 27 differentially expressed proteins (DEPs) via Cytoscape 3.7.1 and its plug-ins was constructed and analyzed.
Results: Ten proteins were introduced as hub-bottlenecks among which four were from DEPs. The gene ontology analysis also indicated that positive regulation of multi-organism process and regulation of response to biotic stimulus are the most disrupted biological processes of GBC considering their relationships with the DEPs.
Conclusion: ACTG, ALB, GGH, and DYNC1H1, and relative biological terms were introduced as drug targets and possible diagnostic biomarkers.
Keywords: Gallbladder cancer, Protein-protein interaction network analysis, Hub-bottleneck proteins, Biological process.
(Please cite as: Zali MR, Zamanian Azodi M, Razaghi Z, Heydari MH. Gallbladder cancer integrated bioinformatics analysis of protein profile data. Gastroenterol Hepatol Bed Bench 2019;12(Suppl.1):S66-S73).
- Gallbladder cancer
- Protein-protein interaction network analysis
- Hub-bottleneck proteins
- Biological process.
How to Cite
References
Tan Y, Ma SY, Wang FQ, Meng HP, Mei C, Liu A, et al. Proteomic-based analysis for identification of potential serum biomarkers in gallbladder cancer. Oncol Rep 2011;26:853-9.
Wi Y, Woo H, Won YJ, Jang JY, Shin A. Trends in gallbladder cancer incidence and survival in Korea. Cancer Res Treat 2018;50:1444.
Jaruvongvanich V, Yang JD, Peeraphatdit T, Roberts LR. The incidence rates and survival of gallbladder cancer in the USA. Eur J Cancer Prev 2019;28:1-9.
Tuo JY, Zhang M, Zheng RS, Zhang SW, Li GC, Yang NN, et al. Report of incidence and mortality of gallbladder cancer in China, 2014. Zhonghua Zhong Liu Za Zhi 2018;40:894-899.
Nazemalhosseini-Mojarad E, Haghighi A, Taghipour N, Keshavarz A, Mohebi SR, Zali MR, et al. Subtype analysis of Cryptosporidium parvum and Cryptosporidium hominis isolates from humans and cattle in Iran. Vet Parasitol. 2011;179:250-2.
Alizadeh AH, Ranjbar M, Ansari S, MirArab A, Alavian SM, Mohammad K, et al. Seroprevalence of hepatitis B in Nahavand, Islamic Republic of Iran. East Mediterr Health J. 2006;12:528-37.
Mahboubi M, Azodi MZ, Tavirani MR, Mansouri V, Ahmadi NA, Hamdieh M, et al. Protein-Protein Interaction Analysis of Common Top Genes in Obsessive-Compulsive Disorder (OCD) and Schizophrenia: Towards New Drug Approach Obsessive-Compulsive disorder (OCD) and Schizophrenia Comorbidity Gene Analysis. Iran J Pharm Res 2018; S17:173.
Tavirani M, Zamanian-Azodi M, Rezaei-Tavirani M, Vafaee R. Interaction network prediction and analysis of Anorexia Nervosa. Iran J Child Neurol 2019;13:45-54.
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003;13:2498-504.
Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, et al. The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible. Nucleic Acids Res 2017;45:D362-8.
Bindea G, Galon J, Mlecnik B. CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data. Bioinformatics 2013;29:661-3.
Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 2009;25:1091-3.
Bhunia S, Barbhuiya MA, Gupta S, Shrivastava BR, Tiwari PK. Abstract A14: Downregulation of desmin involves gene promoter hypermethylation in gallbladder cancer. AACR; 2018.
Sahasrabuddhe NA, Barbhuiya MA, Bhunia S, Subbannayya T, Gowda H, Advani J, et al. Identification of prosaposin and transgelin as potential biomarkers for gallbladder cancer using quantitative proteomics. Biochem Biophys Res Commun 2014;446:863-9.
Barbhuiya MA, Subbannayya T, Leal-Rojas PA, Shahasrabudhe N, Renuse S, Patil AH, et al. Su1999 Proteomic Analysis of Gallbladder Cancer to Identify Biomarkers and Therapeutic Targets. Gastroenterology 2015;148:571.
Truckenmueller F, Goeppert B, Pusch S, Heinze I, Kirkpatrick J, Schirmacher P, et al., editors. Mass-spectrometric analysis of deregulated proteins in gallbladder carcinoma. Journal of hepatology; 2019: elsevier science bv po box 211, 1000 ae amsterdam, netherlands.
Tan Y, Meng H, Wu Q, Wang F, Wu H. Proteomic study of gallbladder cancer, with special reference on the expression and significance of annexin A3. Zhonghua Bing Li Xue Za Zhi 2010;39:382-6.
Subbannayya T, Leal-Rojas P, Zhavoronkov A, Ozerov IV, Korzinkin M, Babu N, et al. PIM1 kinase promotes gallbladder cancer cell proliferation via inhibition of proline-rich Akt substrate of 40 kDa (PRAS40). J Cell Commun Signal 2019;13:163-77.
Bhunia S, Gupta S, Shrivastava BR, Tiwari PK. Identification of S100 calcium binding protein A9 as a prognostic biomarker in gallbladder cancer. Meta Gene 2018;18:62-7.
Rai R, Gosai S, Rao CV, Chandra V. Molecular Diagnosis of Gall Bladder Cancer. Molecular Diagnostics in Cancer Patient 2019;11-25.
Burotto M, Chiou VL, Lee JM, Kohn EC. The MAPK pathway across different malignancies: a new perspective. Cancer 2014;120:3446-56.
Li XW, Tuergan M, Abulizi G. Expression of MAPK1 in cervical cancer and effect of MAPK1 gene silencing on epithelial-mesenchymal transition, invasion and metastasis. Asian Pac J Trop Med 2015;8:937-43.
Najar AG, Pashaei-Asl R, Omidi Y, Farajnia S, Nourazarian AR. EGFR antisense oligonucleotides encapsulated with nanoparticles decrease EGFR, MAPK1 and STAT5 expression in a human colon cancer cell line. Asian Pac J Cancer Prev 2013;14:495-8.
Reyes-Gibby CC, Wang J, Silvas MRT, Yu R, Yeung S-CJ, Shete S. MAPK1/ERK2 as novel target genes for pain in head and neck cancer patients. BMC Genetics 2016;17:40.
Mohri D, Ijichi H, Miyabayashi K, Takahashi R, Kudo Y, Sasaki T, et al. A potent therapeutics for gallbladder cancer by combinatorial inhibition of the MAPK and mTOR signaling networks. J Gastroenterol 2016;51:711-21.
Buchegger K, Silva R, López J, Ili C, Araya JC, Leal P, et al. The ERK/MAPK pathway is overexpressed and activated in gallbladder cancer. Pathol Res Pract. 2017;213:476-82.
Luger T, Kokoschka E, Sagaster P, Micksche M. Serum lysozyme levels in patients with solid tumors. Oncology 1979;36:15-8.
Serra C, Vizoso F, Alonso L, Rodríguez JC, González LO, Fernández M, et al. Expression and prognostic significance of lysozyme in male breast cancer. Breast Cancer Res 2002;4:R16.
Sai K, Onda M, Ozawa Y, Honjo T, Okuda T, Sumiyama Y. Relationship between metaplastic changes and occurrence of endocrin cells, lysozyme and lactoferrin in gallbladder carcinoma. Ann Cancer Res Ther 1998;7:34-8.
Sucularli C, Arslantas M. Computational prediction and analysis of deleterious cancer associated missense mutations in DYNC1H1. Mol Cell Probes 2017;34:21-9.
Gong LB, Wen T, Li Z, Xin X, Che XF, Wang J, et al. DYNC1I1 Promotes the Proliferation and Migration of Gastric Cancer by Up-Regulating IL-6 Expression. Front Oncol 2019;9.
Guo C, Liu S, Wang J, Sun MZ, Greenaway FT. ACTB in cancer. Clin Chim Acta 2013;417:39-44.
Yang L, Yang Z, Tan X, Miao X. Expression of annexin A1 (ANXA1) and A2 (ANXA2) and its significance in benign and malignant lesions of gallbladder. Zhonghua zhong liu za zhi 2010;32:595-9.
Wang CY, Lin CF. Annexin A2: its molecular regulation and cellular expression in cancer development. Dis Markers 2014;2014.
Christensen MV, Høgdall CK, Jochumsen KM, Høgdall EV. Annexin A2 and cancer: A systematic review. Int J Oncol 2018;52:5-18.
Melling N, Rashed M, Schroeder C, Hube-Magg C, Kluth M, Lang D, et al. High-Level γ-Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer. Int J Mol Sci 2017;18:286.
Shubbar E, Helou K, Kovács A, Nemes S, Hajizadeh S, Enerbäck C, et al. High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer. BMC Cancer 2013;13:47.
Sadahiro S, Suzuki T, Tanaka A, Okada K, Saito G, Miyakita H, et al. Gene expression levels of gamma-glutamyl hydrolase in tumor tissues may be a useful biomarker for the proper use of S-1 and tegafur-uracil/leucovorin in preoperative chemoradiotherapy for patients with rectal cancer. Cancer Chemother Pharmacol 2017;79:1077-85.
Dong X, Han Y, Sun Z, Xu J. Actin Gamma 1, a new skin cancer pathogenic gene, identified by the biological feature‐based classification. J Cell Biochem 2018;119:1406-19.
Po ‘uha ST, Kavallaris M. Gamma-actin is involved in regulating centrosome function and mitotic progression in cancer cells. Cell Cycle 2015;14:3908-19.
Iqbal MA, Siddiqui FA, Gupta V, Chattopadhyay S, Gopinath P, Kumar B, et al. Insulin enhances metabolic capacities of cancer cells by dual regulation of glycolytic enzyme pyruvate kinase M2. Mol Cancer 2013;12:72.
- Abstract Viewed: 101 times
- PDF Downloaded: 49 times